Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas
Publication in refereed journal


Times Cited
Web of Science279WOS source URL (as at 19/05/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractPurpose: Activating Mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) confer a strong sensitivity to gefitinib, a selective tyrosine kinase inhibitor of EGFR.
All Author(s) ListTaron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T
Journal nameClinical Cancer Research
Year2005
Month8
Day15
Volume Number11
Issue Number16
PublisherAMER ASSOC CANCER RESEARCH
Pages5878 - 5885
ISSN1078-0432
eISSN1557-3265
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesOncology; ONCOLOGY

Last updated on 2020-20-05 at 03:06